In a report launched on September 29, Nicolas Pauillac from Kepler Capital maintained a Purchase score on Nyxoah (NYXH – Research Report), with a value goal of €12.00. The corporate’s shares closed final Friday at $7.05.
In response to TipRanks, Pauillac is ranked #5403 out of 8482 analysts.
The phrase on The Avenue basically, suggests a Robust Purchase analyst consensus score for Nyxoah with a $12.02 common value goal, which is a 70.50% upside from present ranges. In a report launched on September 29, H.C. Wainwright additionally reiterated a Purchase score on the inventory with a $15.00 value goal.
The corporate has a one-year excessive of $10.34 and a one-year low of $4.36. At the moment, Nyxoah has a median quantity of three,052.
TipRanks has tracked 36,000 firm insiders and located that a number of of them are higher than others with regards to timing their transactions. See which 3 stocks are most probably to make strikes following their insider actions.
Nyxoah (NYXH) Firm Description:
Nyxoah SA is a health-technology firm centered on the event and commercialization of options and companies to deal with sleep disordered respiration situations. Nyxoah’s answer platform relies on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation remedy to deal with average to extreme Obstructive Sleep Apnea (OSA), the frequent sleep disordered respiration situation that’s related to elevated mortality danger and comorbidities together with cardiovascular ailments, despair and stroke.
Learn Extra on NYXH: